{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:59:01Z","timestamp":1793059141138,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12325-026-03523-5","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:35:02Z","timestamp":1773336902000},"page":"2090-2105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5622-0203","authenticated-orcid":false,"given":"Andreea","family":"Ciudin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2602-8450","authenticated-orcid":false,"given":"Helene","family":"Sapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-8025","authenticated-orcid":false,"given":"Ludi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6662-804X","authenticated-orcid":false,"given":"Georgios K.","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6687-1921","authenticated-orcid":false,"given":"Sarah","family":"Zimner-Rapuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Curteis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-2420","authenticated-orcid":false,"given":"Laura J.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3178-1622","authenticated-orcid":false,"given":"Erin","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"3523_CR1","unstructured":"World Health Organization (WHO). Obesity and Overweight Fact Sheet. 2025. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed 05 Jan 2026."},{"issue":"8","key":"3523_CR2","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1111\/dom.15077","volume":"25","author":"M Bl\u00fcher","year":"2023","unstructured":"Bl\u00fcher M, Aras M, Aronne LJ, et al. New insights into the treatment of obesity. Diabetes Obes Metab. 2023;25(8):2058\u201372.","journal-title":"Diabetes Obes Metab"},{"key":"3523_CR3","unstructured":"National Institute for Health and Care Excellence (NICE). Overweight and obesity management. NICE guideline [NG246]. 2025. https:\/\/www.nice.org.uk\/guidance\/ng246. Accessed 05 Jan 2026."},{"issue":"6","key":"3523_CR4","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000442721","volume":"8","author":"V Yumuk","year":"2015","unstructured":"Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402\u201324.","journal-title":"Obes Facts"},{"key":"3523_CR5","unstructured":"Dietz WH, Belay B, Bradley D, et al. A model framework that integrates community and clinical systems for the prevention and management of obesity and other chronic diseases. NAM Perspectives Discussion Paper, National Academy of Medicine, Washington, DC. 2017."},{"issue":"31","key":"3523_CR6","doi-asserted-by":"publisher","first-page":"E875","DOI":"10.1503\/cmaj.191707","volume":"192","author":"S Wharton","year":"2020","unstructured":"Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. Can Med Assoc J. 2020;192(31):E875\u201391.","journal-title":"Can Med Assoc J"},{"key":"3523_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03095-3","author":"L Busetto","year":"2024","unstructured":"Busetto L, Dicker D, Fr\u00fchbeck G, et al. A new framework for the diagnosis, staging and management of obesity in adults. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03095-3.","journal-title":"Nat Med"},{"key":"3523_CR8","unstructured":"National Institute for Health and Care Excellence (NICE). Endoscopic sleeve gastroplasty for obesity. Interventional procedures guidance [IPG783]. 2024. https:\/\/www.nice.org.uk\/guidance\/ipg783. Accessed 05 Jan 2026."},{"issue":"10315","key":"3523_CR9","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/S0140-6736(21)02394-1","volume":"398","author":"BK Abu Dayyeh","year":"2021","unstructured":"Abu Dayyeh BK, Maselli DB, Rapaka B, et al. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet. 2021;398(10315):1965\u201373.","journal-title":"Lancet"},{"key":"3523_CR10","unstructured":"US Food and Drug Administration (FDA). Wegovy (semaglutide) injection for subcutaneous use. Product Label. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215256s023lbl.pdf. Accessed 05 Jan 2026."},{"key":"3523_CR11","unstructured":"European Medicines Agency (EMA). Saxenda. Summary of Product Characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/saxenda-epar-product-information_en.pdf. Accessed 05 Jan 2026."},{"key":"3523_CR12","unstructured":"European Medicines Agency (EMA). Wegovy. Summary of Product Characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/wegovy-epar-product-information_en.pdf. Accessed 05 Jan 2026."},{"key":"3523_CR13","unstructured":"US Food and Drug Administration (FDA). Saxenda (liraglutide). injection for subcutaneous use. Product Label. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/206321s022lbl.pdf. Accessed 05 Jan 2026."},{"key":"3523_CR14","unstructured":"UK Medicines & Healthcare products Regulatory Agency (MHRA). Wegovy. Summary of Product Characteristics. 2025. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/d26dde30f87d24d4e10e6946f0fa08ee3ad715cd. Accessed 27 Feb 2026."},{"key":"3523_CR15","unstructured":"UK Medicines & Healthcare products Regulatory Agency (MHRA). Saxenda. Summary of Product Characteristics. 2025. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/85db577f1b43068321b4548ac817d75b043002be. Accessed 05 Jan 2026."},{"key":"3523_CR16","unstructured":"US Food and Drug Administration (FDA). Zepbound (tirzepatide) injection for subcutaneous use. Product Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217806s031lbl.pdf. Accessed 05 Jan 2026. 2025."},{"key":"3523_CR17","unstructured":"UK Medicines & Healthcare products Regulatory Agency (MHRA). Mounjaro. Summary of Product Characteristics. 2025. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/538c8b3e9062a375a188ca5e85b056ca9e418cb5. Accessed 27 Feb 2026."},{"key":"3523_CR18","unstructured":"European Medicines Agency (EMA). Mounjaro. Summary of Product Characteristics. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mounjaro-epar-product-information_en.pdf. Accessed 05 Jan 2026."},{"issue":"3","key":"3523_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"3523_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26\u201336.","journal-title":"N Engl J Med"},{"key":"3523_CR21","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/oby.24002","volume":"32","author":"XH Pan","year":"2024","unstructured":"Pan XH, Tan B, Chin YH, Lee ECZ, et al. Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis. Obesity (Silver Spring). 2024;32:840\u201356.","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"3523_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13543","volume":"24","author":"OS Alkhezi","year":"2023","unstructured":"Alkhezi OS, Alahmed AA, Alfayez OM, Alzuman OA, Almutairi AR, Almohammed OA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials. Obes Rev. 2023;24(3):e13543.","journal-title":"Obes Rev"},{"issue":"9","key":"3523_CR23","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1111\/dom.15148","volume":"25","author":"CW le Roux","year":"2023","unstructured":"le Roux CW, Hankosky ER, Wang D, Malik R, et al. Tirzepatide 10 and 15\u00a0mg compared with semaglutide 2.4\u00a0mg for the treatment of obesity: an indirect treatment comparison. Diabetes Obes Metab. 2023;25(9):2626\u201333.","journal-title":"Diabetes Obes Metab"},{"key":"3523_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102777","author":"M Anson","year":"2024","unstructured":"Anson M, Henney AE, Broadwell N, et al. Incidence of new onset type\u00a02 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study. EClinicalMedicine. 2024. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102777.","journal-title":"EClinicalMedicine"},{"key":"3523_CR25","unstructured":"University of York: Centre for Reviews and Dissemination. Systematic Reviews: CRD's guidance for undertaking reviews in health care. 2008."},{"key":"3523_CR26","unstructured":"Higgins JPT, Thomas J, Chandler J, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). 2022."},{"key":"3523_CR27","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Bossuyt PM, Boutron I, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj. 2021;372:n71.","journal-title":"bmj"},{"key":"3523_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JA Sterne","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"3523_CR29","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria. 2022."},{"key":"3523_CR30","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades A. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2011."},{"key":"3523_CR31","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU Technical Support Document 3: Heterogeneity: Subgroups, Meta-Regression, Bias And Bias-Adjustment. 2011."},{"key":"3523_CR32","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. 2014."},{"key":"3523_CR33","unstructured":"HTA CG | Member State Coordination Group on Health Technology Assessment. Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons. 2024."},{"key":"3523_CR34","unstructured":"European Medicines Agency (EMA). ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. 2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-ich-e9-r1-addendum-estimands-and-sensitivity-analysis-clinical-trials-guideline-statistical-principles-clinical-trials-step-2b-revision-1_en.pdf. Accessed 05 Jan 2026."},{"issue":"6","key":"3523_CR35","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/sim.6381","volume":"34","author":"RM Turner","year":"2015","unstructured":"Turner RM, Jackson D, Wei Y, Thompson SG, Higgins JP. Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis. Stat Med. 2015;34(6):984\u201398.","journal-title":"Stat Med"},{"key":"3523_CR36","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002.","journal-title":"N Engl J Med"},{"key":"3523_CR37","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083\u201391.","journal-title":"Nat Med"},{"key":"3523_CR38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"326","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP\u00a08 randomized clinical trial. JAMA. 2022;326:138\u201350.","journal-title":"JAMA"},{"key":"3523_CR39","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O'Neil","year":"2018","unstructured":"O\u2019Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase\u00a02 trial. Lancet. 2018;392:637\u201349.","journal-title":"Lancet"},{"key":"3523_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, et al. SCALE obesity and prediabetes NN8022\u20131839 study group a randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management. N Engl J Med. 2015;373:11\u201322.","journal-title":"N Engl J Med"},{"key":"3523_CR41","unstructured":"National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity (TA875). 2022. https:\/\/www.nice.org.uk\/guidance\/ta875\/evidence\/appraisal-consultation-committee-papers-pdf-11381311261. Accessed 05 Jan 2026."},{"key":"3523_CR42","unstructured":"Eli Lilly. Efficacy and Safety of Tirzepatide Once Weekly in Participants without Type\u00a02 Diabetes Who Have Obesity or Are Overweight with Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1) Full Clinical Study Report. 2022."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03523-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03523-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03523-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:38:08Z","timestamp":1778229488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03523-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3523"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03523-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andreea Ciudin: Honoraria from AstraZeneca, Boehringer Ingelheim, Lilly, Novo Nordisk; Member of the DMC of Boehringer Ingelheim clinical trials-SYNCRONIZE program; Helene Sapin, Ludi Fan, Georgios K. Dimitriadis, Sarah Zimner-Rapuch, Erin Johansson: Employees and shareholders of Eli Lilly and Company; Tristan Curteis, Laura J. Clark, Manon Rubinstein: Employees of Costello Medical, which received payment from Eli Lilly and Company for analytical services for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}